Publikationsverzeichnis von Prof. Dr. med. Gerhard Held

Die fünf wichtigsten Publikationen

  • Poeschel, V., G. Held, M. Ziepert, M. Witzens-Harig, H. Holte, L. Thurner, P. Borchmann, A. Viardot, M. Soekler, U. Keller, C. Schmidt, L. Truemper, R. Mahlberg, R. Marks, H.-G. Hoeffkes, B. Metzner, J. Dierlamm, N. Frickhofen, M. Haenel, A. Neubauer, M. Kneba, F. Merli, A. Tucci, P. de Nully Brown, M. Federico, E. Lengfelder, A. di Rocco, R. Trappe, A. Rosenwald, C. Berdel, M. Maisenhoelder, O. Shpilberg, J. Amam, K. Christofyllakis, F. Hartmann, N. Murawski, S. Stilgenbauer, M. Nickelsen, G. Wulf, B. Glass, N. Schmitz, B. Altmann, M. Loeffler and M. Pfreundschuh (2019). "Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial." The Lancet 394(10216): 2271-2281.
  • Held, G., I. F. Luescher, F. Neumann, C. Papaioannou, T. Schirrmann, M. Sester, S. Smola and M. Pfreundschuh (2015). "MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies." J Immunol 195(9): 4210-4217.
  • Held, G., N. Murawski, M. Ziepert, J. Fleckenstein, V. Poschel, C. Zwick, J. Bittenbring, M. Hanel, S. Wilhelm, J. Schubert, N. Schmitz, M. Loffler, C. Rube and M. Pfreundschuh (2014). "Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma." Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32(11): 1112-1118.
  • Held, G., S. Zeynalova, N. Murawski, M. Ziepert, B. Kempf, A. Viardot, M. Dreyling, M. Hallek, M. Witzens-Harig, J. Fleckenstein, C. Rube, C. Zwick, B. Glass, N. Schmitz and M. Pfreundschuh (2013). "Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement." Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31(32): 4115-4122.
  • Held, G., A. Wadle, N. Dauth, G. Stewart-Jones, C. Sturm, M. Thiel, C. Zwick, D. Dieckmann, G. Schuler, H. R. Hoogenboom, F. Levy, V. Cerundolo, M. Pfreundschuh and C. Renner (2007). "MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing." European journal of immunology 37(7): 2008-2017.

2020

  • Staiger, A. M., M. Altenbuchinger, M. Ziepert, C. Kohler, H. Horn, M. Huttner, K. S. Hüttl, G. Glehr, W. Klapper, M. Szczepanowski, J. Richter, H. Stein, A. C. Feller, P. Möller, M.-L. Hansmann, V. Poeschel, G. Held, M. Loeffler, N. Schmitz, L. Trümper, T. Pukrop, A. Rosenwald, G. Ott, R. Spang, M. Loeffler, R. Siebert, W. Klapper, R. Spang, L. Trümper, M. Pfreundschuh, N. Schmitz, L. Trümper, M. Loeffler, P. the Emed Demonstrator and G. German High Grade Non-Hodgkin’s Lymphoma Study (2020). "A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL." Leukemia 34(2): 543-552.
  • Ziepert, M., S. Lazzi, R. Santi, F. Vergoni, M. Granai, V. Mancini, A. Staiger, H. Horn, M. Löffler, V. Pöschel, G. Held, G. Wulf, L. H. Trümper, N. Schmitz, A. Rosenwald, E. Sabattini, K. N. Naresh, H. Stein, G. Ott and L. Leoncini (2020). "A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients." Haematologica: haematol.2019.235556.

2019

  • Held, G. and B. Glass (2019). "Diffuses großzelliges B-Zell-Lymphom: Primär- und Rezidivtherapie." Der Onkologe 10: 880-891.
  • Poeschel, V., G. Held, M. Ziepert, M. Witzens-Harig, H. Holte, L. Thurner, P. Borchmann, A. Viardot, M. Soekler, U. Keller, C. Schmidt, L. Truemper, R. Mahlberg, R. Marks, H.-G. Hoeffkes, B. Metzner, J. Dierlamm, N. Frickhofen, M. Haenel, A. Neubauer, M. Kneba, F. Merli, A. Tucci, P. de Nully Brown, M. Federico, E. Lengfelder, A. di Rocco, R. Trappe, A. Rosenwald, C. Berdel, M. Maisenhoelder, O. Shpilberg, J. Amam, K. Christofyllakis, F. Hartmann, N. Murawski, S. Stilgenbauer, M. Nickelsen, G. Wulf, B. Glass, N. Schmitz, B. Altmann, M. Loeffler and M. Pfreundschuh (2019). "Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial." The Lancet 394(10216): 2271-2281.
  • Schlenk, R. F., D. Weber, W. Fiedler, H. R. Salih, G. Wulf, H. Salwender, T. Schroeder, T. Kindler, M. Lübbert, D. Wolf, J. Westermann, D. Kraemer, K. S. Götze, H.-A. Horst, J. Krauter, M. Girschikofsky, M. Ringhoffer, T. Südhoff, G. Held, H.-G. Derigs, R. Schroers, R. Greil, M. Grießhammer, E. Lange, A. Burchardt, U. Martens, B. Hertenstein, L. Marretta, M. Heuser, F. Thol, V. I. Gaidzik, W. Herr, J. Krzykalla, A. Benner, K. Döhner, A. Ganser, P. Paschka, H. Döhner and o. b. o. t. G.-A. A. S. Group (2019). "Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD." Blood 133(8): 840-851.
  • Wulf, G., J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen, A. Leha, M. Pfreundschuh, N. Schmitz, L. Trümper and B. Glass (2019). "Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease." Bone Marrow Transplantation 54(6): 877-884.

2018

  • Avivi, I., L. Arcaini, V. V. Ferretti, A. Boumendil, H. Finel, G. Milone, F. Zaja, D. Liliana, M. Musso, B. Didier, E. Bachy, M. Wattad, E. Nicolas-Virelizier, M. Gramatzki, J.-H. Bourhis, D. Caillot, A. Haenel, G. Held, C. Thieblemont, P. Jindra, D. Pohlreich, F. Guilhot, F. Kroschinsky, B. Wahlin, C. Scheid, N. Ifrah, C. Berthou, P. Dreger, S. Montoto and A. Conconi (2018). "High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO." British Journal of Haematology 182(6): 807-815.
  • Gaidzik, V. I., D. Weber, P. Paschka, A. Kaumanns, S. Krieger, A. Corbacioglu, J. Krönke, S. Kapp-Schwoerer, D. Krämer, H. A. Horst, I. Schmidt-Wolf, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, T. Kindler, W. Fiedler, M. Wattad, R. F. Schlenk, L. Bullinger, V. Teleanu, B. Schlegelberger, F. Thol, M. Heuser, A. Ganser, H. Döhner, K. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2018). "DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia." Leukemia 32(1): 30-37.

2017

  • Jahn, N., M. Agrawal, L. Bullinger, D. Weber, A. Corbacioglu, V. I. Gaidzik, L. Schmalbrock, F. Thol, M. Heuser, J. Krauter, G. Göhring, A. Kündgen, W. Fiedler, M. Wattad, G. Held, C. H. Köhne, H. A. Horst, M. Lübbert, A. Ganser, R. F. Schlenk, H. Döhner, K. Döhner and P. Paschka (2017). "Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group." Leukemia 31(4): 1012-1015.
  • Jaramillo, S., A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C. H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H. A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk and G. for the German-Austrian Acute Myeloid Leukemia Study (2017). "Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia." Blood Cancer Journal 7(5): e564-e564.
  • Neuenhahn, M., J. Albrecht, M. Odendahl, F. Schlott, G. Dössinger, M. Schiemann, S. Lakshmipathi, K. Martin, D. Bunjes, S. Harsdorf, E. M. Weissinger, H. Menzel, M. Verbeek, L. Uharek, N. Kröger, E. Wagner, G. Kobbe, T. Schroeder, M. Schmitt, G. Held, W. Herr, L. Germeroth, H. Bonig, T. Tonn, H. Einsele, D. H. Busch and G. U. Grigoleit (2017). "Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT." Leukemia 31(10): 2161-2171.
  • Schlenk, R. F., P. Frech, D. Weber, P. Brossart, H. A. Horst, D. Kraemer, G. Held, M. Ringhoffer, A. Burchardt, G. Kobbe, K. Götze, D. Nachbaur, T. Fischer, M. Lübbert, H. R. Salih, H. Salwender, G. Wulf, E. Koller, M. Wattad, W. Fiedler, S. Kremers, H. Kirchen, B. Hertenstein, P. Paschka, V. I. Gaidzik, V. Teleanu, M. Heuser, F. Thol, K. Döhner, J. Krauter, A. Ganser, H. Döhner and A. and for the German-Austrian (2017). "Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia." Leukemia 31(5): 1217-1220.
  • Wattad, M., D. Weber, K. Döhner, J. Krauter, V. I. Gaidzik, P. Paschka, M. Heuser, F. Thol, T. Kindler, M. Lübbert, H. R. Salih, A. Kündgen, H. A. Horst, P. Brossart, K. Götze, D. Nachbaur, C. H. Köhne, M. Ringhoffer, G. Wulf, G. Held, H. Salwender, A. Benner, A. Ganser, H. Döhner, R. F. Schlenk and A. for the German-Austrian (2017). "Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure." Leukemia 31(6): 1306-1313.

2016

  • Gaidzik, V. I., V. Teleanu, E. Papaemmanuil, D. Weber, P. Paschka, J. Hahn, T. Wallrabenstein, B. Kolbinger, C. H. Köhne, H. A. Horst, P. Brossart, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, M. Rummel, M. Gerstung, P. Campbell, J. M. Kraus, H. A. Kestler, F. Thol, M. Heuser, B. Schlegelberger, A. Ganser, L. Bullinger, R. F. Schlenk, K. Döhner, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "Erratum: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features." Leukemia 30(11): 2282-2282.
  • Gaidzik, V. I., V. Teleanu, E. Papaemmanuil, D. Weber, P. Paschka, J. Hahn, T. Wallrabenstein, B. Kolbinger, C. H. Köhne, H. A. Horst, P. Brossart, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, M. Rummel, M. Gerstung, P. Campbell, J. M. Kraus, H. A. Kestler, F. Thol, M. Heuser, B. Schlegelberger, A. Ganser, L. Bullinger, R. F. Schlenk, K. Döhner, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features." Leukemia 30(11): 2160-2168.
  • Schlenk, R. F., M. Lübbert, A. Benner, A. Lamparter, J. Krauter, W. Herr, H. Martin, H. R. Salih, A. Kündgen, H.-A. Horst, P. Brossart, K. Götze, D. Nachbaur, M. Wattad, C.-H. Köhne, W. Fiedler, M. Bentz, G. Wulf, G. Held, B. Hertenstein, H. Salwender, V. I. Gaidzik, B. Schlegelberger, D. Weber, K. Döhner, A. Ganser, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study." Annals of Hematology 95(12): 1931-1942.
  • Theis, F., A. Corbacioglu, V. I. Gaidzik, P. Paschka, D. Weber, L. Bullinger, M. Heuser, A. Ganser, F. Thol, B. Schlegelberger, G. Göhring, C. H. Köhne, U. Germing, P. Brossart, H. A. Horst, D. Haase, K. Götze, M. Ringhoffer, W. Fiedler, D. Nachbaur, T. Kindler, G. Held, M. Lübbert, M. Wattad, H. R. Salih, J. Krauter, H. Döhner, R. F. Schlenk and K. Döhner (2016). "Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group." Leukemia 30(11): 2248-2250.
  • Vrhovac, R., M. Labopin, F. Ciceri, J. Finke, E. Holler, J. Tischer, B. Lioure, J. Gribben, L. Kanz, D. Blaise, P. Dreger, G. Held, R. Arnold, A. Nagler and M. Mohty (2016). "Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes." Bone Marrow Transplant 51(2): 186-193.

Älter als 2016

Erst-, Zweit- und Senior-Autorenschaften sind fett markiert. Die Publikationen sind chronologisch geordnet.

  1. Rogacev KS, Zawada AM, Hundsdorfer J, Achenbach M, Held G, Fliser D, Heine GH. 2015. Immunosuppression and monocyte subsets. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 30: 143-53
  2. Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Spath D, Teleanu V, Kundgen A, Kohne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Gotze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Dohner H, Dohner K. 2015. ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study of the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica
  3. Kubuschok B, Held G, Pfreundschuh M. 2015. Management of Diffuse Large B-Cell Lymphoma (DLBCL). Cancer treatment and research 165: 271-88
  4. Kittner JM, von Bialy L, Wiltink J, Thomaidis T, Gospodinov B, Rieke A, Katz F, Discher T, Rath K, Claus B, Held G, Friese G, Schappert B, Schuchmann M, Galle PR. 2015. Lack of awareness in both patients and physicians contributes to a high rate of late presentation in a South West German HIV patient cohort. Infection
  5. Held G, Luescher IF, Neumann F, Papaioannou C, Schirrmann T, Sester M, Smola S, Pfreundschuh M. 2015. MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies. J Immunol 195: 4210-7
  6. Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A, Ziepert M, Ueda R, Pfreundschuh M, Preuss KD. 2014. Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM. International journal of cancer. Journal international du cancer 135: 934-8
  7. Thurner L, Stoger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M. 2014. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Digestive diseases and sciences 59: 1733-42
  8. Tassara M, Dohner K, Brossart P, Held G, Gotze K, Horst HA, Ringhoffer M, Kohne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Gottlicher M, Dohner H, Schlenk RF. 2014. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123: 4027-36
  9. Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, Smola S, Schmidt-Chanasit J. 2014. First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 19
  10. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lubbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Gotze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Spath D, Benner A, Krauter J, Ganser A, Dohner H, Dohner K. 2014. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124: 3441-9
  11. Preuss KD, Fadle N, Regitz E, Held G, Pfreundschuh M. 2014. Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits. International journal of cancer. Journal international du cancer 135: 2046-53
  12. Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. 2014. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32: 4127-33
  13. Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N. 2014. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123: 640-6
  14. Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hanel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trumper L, Rixecker T, Zwick C. 2014. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 25: 1800-6
  15. Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, Witzens-Harig M, Mahlberg R, Rube C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M. 2014. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood 124: 720-8
  16. Hohloch K, Zeynalova S, Held G, Ziepert M, Loeffler M, Wulf G, Schmitz N, Pfreundschuh M, Trumper L. 2014. Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens. Leukemia 28: 2260-3
  17. Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M. 2014. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32: 1112-8
  18. Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M. 2014. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32: 3242-8
  19. Achenbach M, Bittenbring JT, Ziepert M, Regitz E, Ott G, Rosenwald A, Pfreundschuh M, Altmann B, Held G. 2014. Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas. British journal of haematology 167: 430-4
  20. Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, Fox BA, Renner C, Petrausch U. 2013. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene therapy 20: 386-95
  21. Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Gohring G, Kundgen A, Held G, Gotze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Dohner H, Cornelissen JJ, Dohner K, Lowenberg B. 2013. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood
  22. Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Kohne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Gotze K, Horst HA, Ringhoffer M, Lubbert M, Wattad M, Salih HR, Kundgen A, Dohner H, Dohner K. 2013. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 121: 170-7
  23. Neumann F, Kaddu-Mulindwa D, Widmann T, Preuss KD, Held G, Zwick C, Roemer K, Pfreundschuh M, Kubuschok B. 2013. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer immunology, immunotherapy: CII 62: 1211-22
  24. Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, Van Den Broek M, Renner C, Mischo A, Petrausch U. 2013. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system. Anticancer research 33: 4189-201
  25. Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rube C, Zwick C, Glass B, Schmitz N, Pfreundschuh M. 2013. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31: 4115-22
  26. Almunia C, Bretaudeau M, Held G, Babon A, Marchetti C, Castelli FA, Menez A, Maillere B, Gillet D. 2013. Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. PloS one 8: e67645
  27. Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, Gualandi F, Gruhn B, Ouyang J, Rzepecki P, Held G, Sampol A, Voswinkel J, Ljungman P, Fassas A, Badoglio M, Saccardi R, Farge D. 2013. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 22: 245-53
  28. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lubbert M, Frohling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Dohner K, Dohner H. 2012. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119: 2114-21
  29. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. 2012. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119: 3276-84
  30. Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gartner B, Konig J, Murawski N, Held G, Zwick C, Neumann F. 2012. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial. Human gene therapy 23: 1224-36
  31. Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Gotze K, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Teleanu V, Ganser A, Dohner H, Schlenk RF. 2012. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119: 551-8
  32. Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Gotze K, Dohner H, Schlenk RF, Bullinger L, Dohner K. 2012. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30: 1350-7
  33. Preuss KD, Pfreundschuh M, Fadle N, Regitz E, Raudies S, Murwaski N, Ahlgrimm M, Bittenbring J, Klotz M, Schafer KH, Held G, Neumann F, Grass S. 2011. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A. Blood 118: 3340-6
  34. Meissner M, Obmann VC, Hoschke M, Link S, Jung M, Held G, Philipp SE, Zimmermann R, Flockerzi V. 2011. Lessons of Studying TRP Channels with Antibodies. In TRP Channels, ed. MX Zhu. Boca Raton (FL)
  35. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Spath D, Lubbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Gohring G, Schlegelberger B, Dohner H, Dohner K. 2011. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 2709-16
  36. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kundgen A, Gotze K, Rummel M, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Zucknick M, Ganser A, Dohner H, Schlenk RF. 2011. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117: 2137-45
  37. Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, Odunsi K, Shrikant PA, Knuth A, Cerundolo V, Renner C. 2010. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. Yeast 27: 919-31
  38. Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M, Bittenbring J, Schubert J, Neumann F, Pfreundschuh M. 2009. Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens. Annals of hematology 88: 999-1003
  39. Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B, Bittenbring J, Ahlgrimm M, Neumann F, Preuss KD, Pfreundschuh M. 2009. Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. Journal of cancer research and clinical oncology 135: 1207-13
  40. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Nuber N, Stenner-Liewen F, Bauer S, McMichael A, Knuth A, Abken H, Hombach AA, Cerundolo V, Jones EY, Renner C. 2009. Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America 106: 5784-8
  41. Neumann F, Sturm C, Hulsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G. 2009. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor. Immunology letters 125: 86-92
  42. Held G, Pfreundschuh M. 2009. Hematology: germinal center or nongerminal center DLBCL? Nature reviews. Clinical oncology 6: 188-90
  43. Voswinkel J, Kerkdijk AJ, Mueller A, Assmann G, Pfreundschuh M, Held G. 2008. A novel system to test for specificity of B cell receptors from tissue of Wegener's granulomatosis patients. Clinical and experimental rheumatology 26: S90-6
  44. 44. Voswinkel J, Assmann G, Held G, Pitann S, Gross WL, Holl-Ulrich K, Herlyn K, Mueller A. 2008. Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clinical and experimental immunology 154: 339-45
  45. Held G, Schubert J, Pfreundschuh M. 2008. [Treatment of hematological malignancies with monoclonal antibodies]. Der Internist 49: 929-30, 32-4, 36-7
  46. Held G, Neumann F, Sturm C, Kaestner L, Dauth N, de Bruijn DR, Renner C, Lipp P, Pfreundschuh M. 2008. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. International journal of cancer. Journal international du cancer 123: 1841-7
  47. Preuss KD, Held G, Kubuschok B, Hung CZ, Malatsidze N, Wagner M, Pfreundschuh M. 2007. Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS. International journal of cancer. Journal international du cancer 121: 459-61
  48. Held G, Wadle A, Dauth N, Stewart-Jones G, Sturm C, Thiel M, Zwick C, Dieckmann D, Schuler G, Hoogenboom HR, Levy F, Cerundolo V, Pfreundschuh M, Renner C. 2007. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing. European journal of immunology 37: 2008-17
  49. Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C. 2006. Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine 24: 6272-81
  50. Held G, Schubert J, Reiser M, Pfreundschuh M. 2006. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Seminars in hematology 43: 221-9
  51. Held G, Poschel V, Pfreundschuh M. 2006. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert review of anticancer therapy 6: 1175-86
  52. Hulsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A. 2005. A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3. The Journal of biological chemistry 280: 2972-80
  53. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. The Journal of experimental medicine 201: 1243-55
  54. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C. 2004. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. European journal of immunology 34: 2919-29
  55. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, Konig J, Bauer S, Kloft M, Pfreundschuh M. 2001. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clinical cancer research: an official journal of the American Association for Cancer Research 7: 1873-81
  56. Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K, Pfreundschuh M. 1999. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer research 59: 1961-5
  57. Renner C, Pfitzenmeier JP, Gerlach K, Held G, Ohnesorge S, Sahin U, Bauer S, Pfreundschuh M. 1997. RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells. Journal of immunology 159: 1276-83
  58. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. 1997. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer immunology, immunotherapy : CII 44: 70-6
  59. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. 1997. Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiology 197: 122-32
  60. Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M. 1996. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88: 236-41
  61. Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M. 1996. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 87: 2930-7